With time running out in the 2022 congressional session, a bipartisan coalition of lawmakers and infectious disease specialists is scrambling to pass a bill aimed at spurring the development of antibiotics to combat the deadly spread of drug-resistant pathogens.
The PASTEUR Act, as amended, would provide $6 billion in federal funding over several years to give drugmakers incentive to develop and manufacture lifesaving medications for the small but growing number of infections highly resistant to antibiotics.
A range of supporters in the health care and drug sectors say the measure would fix the “broken market” for antibiotics by providing stable funding for an industry that tends to focus its research on areas considered good business opportunities. In recent years, most major drug companies have abandoned antibiotic development due to lackluster sales, and several smaller ones involved in the work have declared bankruptcy.
